The Role of PARP Inhibitors in Advanced Prostate Cancer

Thursday, April 27, 2023

5:30 PM – 7:30 PM CST

Location: S104

Course Director(s)

Ashley Ross, MD, PHD

Northwestern Feinberg School of Medicine

Faculty(s)

Kristen Scarpato, MD,FACS,MPH

Vanderbilt University Medical Center
Nancy Davis, MD

Associate Professor of Medicine & Urology
Vanderbilt University Medical Center

A joint symposium will be presented in partnership with the Society of Urologic Oncology (SUO). The symposium will address the role of PARP Inhibitor treatment, as well as evidence and outcomes of PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline.

The symposium is FREE. Registration for AUA23 is required but will not guarantee a spot. Be sure to pick up your AUA2023 badge at the AUA Annual Meeting Main Registration prior to attending this program. It is required for admittance. Spots will be available on a first come first served basis.

Independent educational grant support provided by Pfizer Inc.

Learning Objectives:

Review recommended criteria for genetic testing of prostate cancer patients and how to interpret these tests.
Explain the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment.
Describe the role of PARP Inhibitor treatment alone and in combination with androgen receptor targeted therapies.
Review the evidence and outcomes on PARP Inhibitors as outlined in the newly amended Advanced Prostate Cancer: AUA/SUO Guideline.
Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.